SCHEMBL4890833

SCHEMBL4890833

Nc1ccccc1NC(=O)c1ccc(I)cc1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 18/20 0.77
HDAC3 O15379 10/20 0.77
HDAC2 Q92769 10/20 0.77
MAPK1 P28482 1/20 0.77
NCOR2 Q9Y618 4/20 0.73
PTGS1 P23219 1/20 0.69
HDAC4 P56524 3/20 0.67
HDAC7 Q8WUI4 3/20 0.67
HDAC10 Q969S8 3/20 0.67
HDAC11 Q96DB2 3/20 0.67
HDAC8 Q9BY41 3/20 0.67
HDAC6 Q9UBN7 3/20 0.67
HDAC9 Q9UKV0 3/20 0.67
HDAC5 Q9UQL6 3/20 0.67
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8401704 0.93 HDAC1 (0.89) HDAC1HDAC3HDAC2MAPK1NCOR2
SCHEMBL1060598 0.87 HDAC1 (0.79) HDAC1HDAC3HDAC2MAPK1NCOR2
Dinaline SCHEMBL93636 0.87 HDAC1 (0.79) HDAC1HDAC3HDAC2MAPK1NCOR2
Dinaline SCHEMBL29354254 0.87 HDAC1 (0.79) HDAC1HDAC3HDAC2MAPK1NCOR2
SCHEMBL407834 0.87 HDAC1 (1.00) HDAC1HDAC3HDAC2MAPK1NCOR2
SCHEMBL30363156 0.87 HDAC1 (1.00) HDAC1HDAC3HDAC2MAPK1NCOR2
SCHEMBL7103601 0.87 MEN1 (0.68) HDAC1HDAC3HDAC2MAPK1NCOR2
SCHEMBL23500754 0.86 HDAC1 (0.83) HDAC1HDAC3HDAC2MAPK1NCOR2
Dinaline SCHEMBL10373837 0.86 HDAC1 (0.77) HDAC1HDAC3HDAC2MAPK1NCOR2
SCHEMBL18361216 0.86 HDAC1 (0.77) HDAC1HDAC3HDAC2MAPK1NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240066038-A1 WNT MODULATORS TO TREAT CENTRAL NERVOUS SYSTEM INJURIES MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2024-02-29 US disclosed
US-7868204-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-7868204-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2011-01-11 US disclosed
US-20080234254-A1 Inhibitors of Histone Deacetylase UNIVERSITY OF LEEDS (GB) 2008-09-25 US disclosed
US-20080234254-A1 Inhibitors of Histone Deacetylase UNIVERSITY OF LEEDS (GB) 2008-09-25 US disclosed
US-20080234254-A1 Inhibitors of Histone Deacetylase UNIVERSITY OF LEEDS (GB) 2008-09-25 US disclosed
EP-1758847-A1 INHIBITORS OF HISTONE DEACETYLASE Cancer Research Technology Limited (GB) 2007-03-07 EP disclosed
WO-2005121073-A1 INHIBITORS OF HISTONE DEACETYLASE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2005-12-22 WO disclosed
WO-2005121073-A1 INHIBITORS OF HISTONE DEACETYLASE CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2005-12-22 WO disclosed
WO-2003024448-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2003-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234254-A1 Inhibitors of Histone Deacetylase HDAC8, HDAC4, HDAC5 HDAC1 4/4885HDAC3 5/4885HDAC2 7/4885
US-20240066038-A1 WNT MODULATORS TO TREAT CENTRAL NERVOUS SYSTEM INJURIES WNT3A, WNT1, WNT3 HDAC1 2360/4885HDAC3 2603/4885HDAC2 2861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.